Emibetuzumab clinical trials
Also written LY2875358.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses emibetuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Ramucirumab (1) · Trametinib (1) · Erlotinib (1) · Gefitinib (1)
Studies
Open first, then newest update. How each study uses emibetuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsCompletedPhase 2Eli Lilly and CompanyNCT01897480Written as LY2875358
- A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced CancerCompletedPhase 1/2Eli Lilly and CompanyNCT02082210Written as Emibetuzumab
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) ParticipantsCompletedPhase 2Eli Lilly and CompanyNCT01900652Written as Emibetuzumab
- A Study of LY2875358 in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01287546Written as LY2875358
- A Study of LY2875358 in Japanese Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01602289Written as LY2875358
- A Study of LY2875358 in Participants With MET Positive, Advanced Gastric CancerCompletedPhase 2Eli Lilly and CompanyNCT01874938Written as LY2875358
Codes
What other systems call emibetuzumab · ClinicalTrials.gg INT000274
- MeSH (NLM) C000599789emibetuzumabOne source NLM
- UNII (FDA) MO4K3GDN1IEMIBETUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q19904056EmibetuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95732EmibetuzumabOne source FDA
- DrugBank DB11849One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599789 | emibetuzumab | One source NLM |
| UNII (FDA) | MO4K3GDN1I | EMIBETUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19904056 | Emibetuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95732 | Emibetuzumab | One source FDA |
| DrugBank | DB11849 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.